New sudan ebola vaccine moves to phase 2 testing
NCT ID NCT06803342
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 33 times
Summary
This study tests a new vaccine against Sudan Ebola virus in 200 healthy adults aged 18 to 70. The vaccine uses a harmless chimpanzee virus to deliver protection. Researchers will check for side effects and measure immune responses to see if the vaccine is safe and works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA SUDAN VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Optimal Research; LLC
Melbourne, Florida, 32934, United States
-
Synexus Clinical Research US, Inc.
Phoenix, Arizona, 85020, United States
-
Synexus Clinical Research US, Inc.
Chicago, Illinois, 60602, United States
-
Synexus Clinical Research US, Inc.
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.